Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

NCT02552121 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02552121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02552121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Lead sponsor
Seagen Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2015
Completion date
December 13, 2017
Enrollment
33 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cervix cancer, endometrium cancer, esophagus cancer, lung cancer (nsclc), ovary cancer, prostate cancer (crpc)